Summer Street Analysts Begin Coverage on Immunomedics Incorporated (IMMU)
Wednesday, August 31, 2021 9:35 AM



Equities research analysts at Summer Street initiated coverage on shares of Immunomedics Incorporated (NASDAQ: IMMU) in a research note to investors on Wednesday. The analysts set a "buy" rating and a $8.00 price target on the stock.

Separately, analysts at Summer Street Research initiated coverage on shares of Immunomedics Incorporated in a research note to investors on Wednesday. They set a "buy" rating and a $8.00 price target on the stock. Also, analysts at Brean Murray initiated coverage on shares of Immunomedics Incorporated in a research note to investors on Wednesday, July 13rd. They set a "buy" rating and a $8.00 price target on the stock.

Shares of Immunomedics Incorporated opened at 3.98 on Thursday. Immunomedics Incorporated has a 52 week low of $2.83 and a 52 week high of $4.47. The stock's 50-day moving average is $3.71 and its 200-day moving average is $3.75. The company has a market cap of $300.0 million.

Immunomedics, Inc. (Immunomedics) is a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has developed a number of advanced technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, it has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Immunomedics has licensed its product candidate, epratuzumab, to UCB S.A. (UCB), for the treatment of all autoimmune disease indications worldwide. In addition, it has licensed its product candidate veltuzumab, in the subcutaneous formulation, to Nycomed GmbH (Nycomed), for the treatment of all non-cancer indications worldwide.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.


 

Sponsors

Advertisement


Advertisement